Cargando…

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor clinical prognosis and limited targeted treatment strategies. Kinase inhibitor screening of a panel of 20 TNBC cell lines uncovered three critical TNBC subgroups: 1) sensitive to only MEK inhibitors; 2) sensitiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Noord, Vera E., McLaughlin, Ronan P., Smid, Marcel, Foekens, John A., Martens, John W. M., Zhang, Yinghui, van de Water, Bob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746778/ https://www.ncbi.nlm.nih.gov/pubmed/31527768 http://dx.doi.org/10.1038/s41598-019-49809-3

Ejemplares similares

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy
por: McLaughlin, Ronan P., et al.
Publicado: (2019)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression
por: He, Jichao, et al.
Publicado: (2020)

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery
por: van der Noord, Vera E., et al.
Publicado: (2022)

Co-regulated gene expression of splicing factors as drivers of cancer progression
por: Koedoot, Esmee, et al.
Publicado: (2019)

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients
por: Liu, Ning Qing, et al.
Publicado: (2016)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Bastiaansen, Anna E. M., et al.
Publicado: (2020)

Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers
por: Weerts, Marjolein J. A., et al.
Publicado: (2018)

Splicing factors control triple-negative breast cancer cell mitosis through SUN2 interaction and sororin intron retention
por: Koedoot, Esmee, et al.
Publicado: (2021)

Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
por: Yu, Jack X, et al.
Publicado: (2007)

High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes
por: Riaz, Muhammad, et al.
Publicado: (2012)

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes
por: Zhang, Yinghui, et al.
Publicado: (2011)

Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells
por: You, Kyu Sic, et al.
Publicado: (2021)

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
por: Hammerl, Dora, et al.
Publicado: (2021)

Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer
por: Liu, Ning Qing, et al.
Publicado: (2014)

Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients
por: van den Berg, Inge, et al.
Publicado: (2021)

Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes
por: Koedoot, Esmee, et al.
Publicado: (2019)

Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia
por: Liu, Qiuyu, et al.
Publicado: (2023)

Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis
por: Weerts, Marjolein J.A., et al.
Publicado: (2016)

Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation
por: Moerkens, Marja, et al.
Publicado: (2014)

Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy
por: Koedoot, Esmee, et al.
Publicado: (2021)

A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds
por: Mustafa, Dana A. M., et al.
Publicado: (2015)

DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells
por: Ansems, Marleen, et al.
Publicado: (2015)

Ferritin Heavy Chain in Triple Negative Breast Cancer: A Favorable Prognostic Marker that Relates to a Cluster of Differentiation 8 Positive (CD8+) Effector T-cell Response
por: Liu, Ning Qing, et al.
Publicado: (2014)

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
por: van den Ende, Nadine S., et al.
Publicado: (2022)

Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells
por: Liu, Qiuyu, et al.
Publicado: (2022)

Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer
por: Matossian, Margarite D., et al.
Publicado: (2021)

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
por: Koh, Siang-Boon, et al.
Publicado: (2021)

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis
por: Procaccia, Shiri, et al.
Publicado: (2017)

Understanding drugs in breast cancer through drug sensitivity screening
por: Uhr, Katharina, et al.
Publicado: (2015)

Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer
por: Zhang, Zhizhu, et al.
Publicado: (2022)

Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems
por: Nagaria, Teddy S., et al.
Publicado: (2017)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
por: Zhang, Ying, et al.
Publicado: (2022)

Differential gene expression and AKT targeting in triple negative breast cancer
por: Lin, Feng-Mao, et al.
Publicado: (2019)

Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like–Induced Protein Changes in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Throughout Disease Progression
por: Bos, Manouk K., et al.
Publicado: (2022)

Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway
por: He, Qinyu, et al.
Publicado: (2023)

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
por: Stewart, A., et al.
Publicado: (2015)

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome
por: de Kruijff, Ingeborg E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k617cq5ok8idh6qpg4e230ejha